291 related articles for article (PubMed ID: 31975160)
1. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
Joshi S; Rathore AS
BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
[TBL] [Abstract][Full Text] [Related]
2. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
4. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
5. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
Nupur N; Chhabra N; Dash R; Rathore AS
MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
[TBL] [Abstract][Full Text] [Related]
6. Assessing analytical comparability of biosimilars: GCSF as a case study.
Nupur N; Singh SK; Narula G; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
[TBL] [Abstract][Full Text] [Related]
7. Charge variant analysis of proposed biosimilar to Trastuzumab.
Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical and biological characterization of a biosimilar trastuzumab.
López-Morales CA; Miranda-Hernández MP; Juárez-Bayardo LC; Ramírez-Ibáñez ND; Romero-Díaz AJ; Piña-Lara N; Campos-García VR; Pérez NO; Flores-Ortiz LF; Medina-Rivero E
Biomed Res Int; 2015; 2015():427235. PubMed ID: 26075238
[TBL] [Abstract][Full Text] [Related]
9. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar.
Kim S; Song J; Park S; Ham S; Paek K; Kang M; Chae Y; Seo H; Kim HC; Flores M
MAbs; 2017; 9(4):704-714. PubMed ID: 28296619
[TBL] [Abstract][Full Text] [Related]
10. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
[TBL] [Abstract][Full Text] [Related]
11. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.
Hutterer KM; Polozova A; Kuhns S; McBride HJ; Cao X; Liu J
BioDrugs; 2019 Jun; 33(3):321-333. PubMed ID: 30972630
[TBL] [Abstract][Full Text] [Related]
12. Analytic characterization of biosimilars.
Sullivan PM; DiGrazia LM
Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
[TBL] [Abstract][Full Text] [Related]
14. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
16. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC.
Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC
Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102
[TBL] [Abstract][Full Text] [Related]
17. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars.
Vishwakarma G; Nupur N; Rathore AS
J Diabetes Sci Technol; 2023 Mar; 17(2):417-427. PubMed ID: 34852652
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
[TBL] [Abstract][Full Text] [Related]
20. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
